Versartis Inc (NASDAQ:VSAR) insider Jay Shepard sold 14,446 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $1.80, for a total value of $26,002.80. Following the completion of the transaction, the insider now directly owns 602,298 shares in the company, valued at approximately $1,084,136.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Versartis Inc (VSAR) opened at $1.80 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52. The company has a market capitalization of $60.88, a PE ratio of -0.46 and a beta of 2.11. Versartis Inc has a 1 year low of $1.60 and a 1 year high of $24.00.

VSAR has been the topic of a number of recent research reports. Cantor Fitzgerald set a $14.00 target price on Versartis and gave the company a “buy” rating in a report on Friday, October 27th. Zacks Investment Research downgraded Versartis from a “hold” rating to a “sell” rating in a report on Sunday, January 21st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $5.63.

Institutional investors and hedge funds have recently modified their holdings of the business. Lord Abbett & CO. LLC increased its position in Versartis by 26.5% in the second quarter. Lord Abbett & CO. LLC now owns 319,854 shares of the biopharmaceutical company’s stock worth $5,582,000 after buying an additional 66,977 shares in the last quarter. First Quadrant L P CA increased its position in Versartis by 1,253.8% in the third quarter. First Quadrant L P CA now owns 120,500 shares of the biopharmaceutical company’s stock worth $295,000 after buying an additional 111,599 shares in the last quarter. Northern Trust Corp increased its position in Versartis by 15.6% in the second quarter. Northern Trust Corp now owns 420,553 shares of the biopharmaceutical company’s stock worth $7,339,000 after buying an additional 56,761 shares in the last quarter. Vanguard Group Inc. increased its position in Versartis by 11.9% in the second quarter. Vanguard Group Inc. now owns 1,121,401 shares of the biopharmaceutical company’s stock worth $19,569,000 after buying an additional 118,894 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Versartis in the third quarter worth about $319,000. Institutional investors and hedge funds own 48.73% of the company’s stock.

WARNING: “Jay Shepard Sells 14,446 Shares of Versartis Inc (VSAR) Stock” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://theolympiareport.com/2018/02/13/jay-shepard-sells-14446-shares-of-versartis-inc-vsar-stock.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.